Agile Therapeutics Inc expected to post a loss of 15  cents a share - Earnings Preview

Agile Therapeutics

25/02/2022 11:57

* Agile Therapeutics Inc  AGRX.OQ   AGRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
28 (estimated). 
    * The Princeton New Jersey-based  company is expected to
report  a
101.8% increase in revenue to $1.511 million from $749 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Agile Therapeutics
Inc is
for a loss of 15 cents per share. For the same quarter last
year, the company reported a loss of 20 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $2.5​, about 88.2% above​ its last closing
price of $0.30. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.19       -0.19      -0.18     Beat    6.5
 Jun. 30 2021  -0.22       -0.22      -0.20     Beat    7.4
 Mar. 31 2021  -0.21       -0.21      -0.20     Beat    6.5​
 Dec. 31 2020  -0.23       -0.22      -0.20     Beat    10.7
 ​​Sep.        -0.18       -0.18      -0.18     Met     -1.1
 30 2020                                                
 Jun. 30 2020  -0.14       -0.14      -0.12     Beat    14.3​
 Mar. 31 2020  -0.09       -0.09      -0.10     Missed  -13.6
 Dec. 31 2019  -0.07       -0.07      -0.10     Missed  -33.3
 This summary was machine generated February 25 at 11:57 GMT. 
All figures in US dollars  unless otherwise stated